MediWound to Report Third Quarter 2025 Financial Results
Conference call and webcast scheduled for Thursday, November 20 at 8:30 a.m. Eastern Time
YAVNE, Israel, November 5, 2025 -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its financial results for the third quarter ended September 30, 2025 on Thursday, November 20, 2025.
Following the release, the Company’s management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update.
Dial-in and call details are as follows:
Conference Call & Webcast Details
Toll-Free: 1-844-676-8833
Israel: 1-809-212373
International: 1-412-634-6869
Webcast: Webcast Link
To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call. An archived version of the webcast will be available for replay on the Investors section of the MediWound website.
About MediWound
MediWound Ltd. (Nasdaq: MDWD) is a global biotechnology company focused on developing and commercializing enzymatic therapies for non-surgical tissue repair. The company’s FDA-approved biologic, NexoBrid®, is indicated for the enzymatic removal of eschar in thermal burns and is marketed in the U.S., European Union, Japan, and other international markets. MediWound is also advancing EscharEx®, a late-stage investigational therapy for the debridement of chronic wounds. EscharEx has demonstrated clinical advantages over the leading enzymatic debridement product and targets a substantial global market opportunity.
For more information, visit www.mediwound.com and follow us on LinkedIn and X (formerly Twitter).
MediWound Contacts: Media Contact:
Hani Luxenburg Daniel Ferry Ellie Hanson
Chief Financial Officer Managing Director Partner
MediWound Ltd. LifeSci Advisors, LLC FINN Partners for MediWound
ir@mediwound.com daniel@lifesciadvisors.com ellie.hanson@finnpartners.com
